Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity

Basit Öğe Kaydı
dc.contributor.authorAskar, N.
dc.contributor.authorCirpan, T.
dc.contributor.authorToprak, E.
dc.contributor.authorKarabulut, B.
dc.contributor.authorSelvi, N.
dc.contributor.authorTerek, M. C.
dc.contributor.authorUslu, R.
dc.contributor.authorSanli, U. A.
dc.contributor.authorGoker, E.
dc.date.accessioned2019-10-27T19:17:57Z
dc.date.available2019-10-27T19:17:57Z
dc.date.issued2006
dc.departmentEge Üniversitesien_US
dc.description.abstractThe objective of this study was to investigate the effect of arsenic trioxide (As2O3) on topoisomerase II levels using western blotting method on MDAH 2774 ovarian carcinoma cell culture. Experimental designs were established to determine the cytotoxic effects of As2O3 on MDAH 2774 cells and the IC50 (fatal dose for the 50% of cells) value. Cytotoxicity experiments were carried out using various concentrations of As2O3. The 2,3-bis[2-methyloxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT) and trypan blue dye-exclusion tests were used to evaluate cytotoxicity. Topoisomerase II expressions were investigated using western blotting method with various concentrations of As2O3. Densitometric analysis of topoisomerase 2 bands was carried out using Quantity One 1-D analysis software (Bio-Rad USA, Life Science Research, Hercules, CA). IC50 value of As2O3 was found to be 5 x 10(-6) M for MDAH 2774 cells. When the bands were evaluated, it was observed that there was a decrease in topoisomerase II levels in MDAH 2774 cells with increasing concentrations of As2O3. It was also observed by the densitometric analysis that topoisomerase II expression ratios of MDAH 2774 cells were decreased by approximately 50% at this concentration. Topoisomerase II levels were significantly decreased with the increasing concentrations of As2O3. Inhibition of topoisomerase II enzyme was one of the antiproliferative influence mechanisms of As2O3.en_US
dc.identifier.doi10.1111/j.1525-1438.2006.00626.xen_US
dc.identifier.endpage1556en_US
dc.identifier.issn1048-891X
dc.identifier.issue4en_US
dc.identifier.pmid16884364en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage1552en_US
dc.identifier.urihttps://doi.org/10.1111/j.1525-1438.2006.00626.x
dc.identifier.urihttps://hdl.handle.net/11454/38511
dc.identifier.volume16en_US
dc.identifier.wosWOS:000239005500009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBlackwell Publishingen_US
dc.relation.ispartofInternational Journal of Gynecological Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectarsenic trioxide (As2O3)en_US
dc.subjectcytotoxicityen_US
dc.subjectovarian carcinoma cellsen_US
dc.subjecttopoisomerase IIen_US
dc.titleArsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicityen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu